Mayne Pharma Inc. has entered into a long-term, exclusive license and supply agreement with Mithra Pharmaceuticals SA for Myring, an intravaginal hormonal contraceptive delivery device.  Under the agreement, Mayne Pharma will have responsibility to market, sell and distribute the product following U.S. FDA approval and Mithra will be responsible for supply.   Myring is a non-biocompatible, flexible, ring-shape device combining etonogestrel and ethinyl estradiol over a three-week period. It is...